Thymosin Alpha-1 is a thymic immune peptide studied across four decades of clinical trials.

The short version

Thymosin Alpha-1 is a small immune messenger — a 28-amino-acid peptide (a short chain of protein building blocks) the body makes in the thymus, the gland that schools the immune system. It does not build muscle and it is not a growth or performance peptide; it is an immune modulator. Its job is to wake up the cells that decide which threats to fight, so the immune system reads danger more clearly. Doctors abroad use a lab-made copy, called thymalfasin, mostly for long-term hepatitis B and to support a worn-down immune system. The research is real and stretches back to the 1970s, but it is uneven: many of the strongest-looking studies are small, and the single largest, most careful sepsis trial found no survival benefit at all. It is not approved in the United States. This site reads that record plainly — including the downsides and who should be careful, which live on the effects page.

What the thymus quietly does, and what this peptide is

There is an organ behind the breastbone that almost no one thinks about: the thymus, where young immune cells are taught the difference between self and threat. Thymosin Alpha-1 is one of the messengers that organ speaks with. It is a 28-amino-acid, N-terminally acetylated peptide — a short, highly acidic protein fragment — cut in the body from a larger precursor protein called prothymosin alpha ^[1]. The acetyl cap on its leading end is not decoration; without it, the molecule goes quiet ^[1]. Allan Goldstein and colleagues first pulled it from calf thymus and read its full sequence in 1977 ^[1]. The lab-made, sequence-identical drug carries the name thymalfasin ^[4].

The machine identifiers are plain: molecular weight 3108.3 Da, CAS number 62304-98-7, length 28 aa. Its circulating level falls with age and drops in several chronic inflammatory states ^[1].

How it works — waking the watchers

The peptide acts at the seam where innate immunity (the fast, general first responders) meets adaptive immunity (the slow, specific memory force). It signals through Toll-like receptors — TLR2 and TLR9, the pattern-sensors that sit on dendritic cells (the immune system's sentinels that show captured threats to T-cells) — pushing those sentinels to mature and present antigen ^[5]. That, in turn, matures T-cells and tips them toward a Th1 response (the cell-killing, infection-clearing program) ^[5].

The quieter half of the story is the counterweight. The same peptide can switch on an enzyme called IDO (indoleamine 2,3-dioxygenase, which breaks down the amino acid tryptophan) to generate regulatory T-cells — the brakes ^[5]. So it can lift a flattened immune system and damp a system that is over-firing. Two arms, one molecule. The mechanism is genuinely understood; the Thymosin Alpha-1 research page traces each pathway to its study.

Where the evidence is strongest — and where it isn't

Four decades of human data sit behind this peptide, and the signal is not uniform. In chronic hepatitis B, combining Thymosin Alpha-1 with antiviral therapy outperformed antiviral therapy alone — hepatitis B e-antigen seroconversion reached 45.1% versus 15.2% across eight trials ^[12]. In severe COVID-19, a retrospective cohort tied treatment to lower mortality (11.11% versus 30.00%) and to the reversal of exhausted T-cells ^[6].

Then the honesty: in sepsis, the largest and most rigorous trial was null. The phase-3 TESTS study — 1,106 adults, double-blind, placebo-controlled — found no significant difference in 28-day mortality (23.4% versus 24.1%; hazard ratio 0.99) ^[3]. An earlier, smaller sepsis trial had looked promising ^[2]; the big one did not confirm it. The peptide is not approved for marketing in the United States ^[4]. Read findings here as study-attributed — described, not promised. The full account of Thymosin Alpha-1 effects, including what people report and who should be cautious, sits one page over.